Summit Therapeutics
(NASDAQ) SMMT
Summit Therapeutics Financials at a Glance
Market Cap
$11.97BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$0.00
Net Income (TTM)
-$1.05B
EPS (TTM)
-$1.60
P/E Ratio
-9.61
Dividend
$0.00
Beta (Volatility)
1.02 (Average)
Dividend
$0.00
Beta (Volatility)
1.02 (Average)
Price
$15.92
Volume
3,922,125.075
Open
$15.50
Price
$15.92
Volume
3,922,125.075
Open
$15.50
Previous Close
$15.93
Daily Range
$15.30 - $15.94
52-Week Range
$12.55 - $30.98
Estimated Earnings Date
Aug 10, 2026
Dividend
$0.00
Beta (Volatility)
1.02 (Average)
Price
$15.92
Volume
3,922,125.075
Open
$15.50
Previous Close
$15.93
Daily Range
$15.30 - $15.94
52-Week Range
$12.55 - $30.98
Estimated Earnings Date
Aug 10, 2026
SMMT News
SMMT: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Summit Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
265
CEO
Robert William Duggan; Mahkam Zanganeh, DDS, MBA
Website
www.smmttx.comHeadquarters
Cambridge, MA 02142, US
SMMT Financials
Key Financial Metrics (TTM)
Gross Margin
0.00%
Operating Margin
0.00%
Net Income Margin
0.00%
Return on Equity
-340.55%
Return on Capital
-216.93%
Return on Assets
-214.23%
Earnings Yield
-10.41%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$11.97BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
776.16M
Volume
3.92M
Avg. Volume
5.40M
Financials (TTM)
Gross Profit
$0.00
Operating Income
-$1.07B
EBITDA
-$1.05B
Operating Cash Flow
-$286.56M
Capital Expenditure
-$360.29K
Free Cash Flow
-$286.92M
Cash & ST Invst.
$454.05M
Total Debt
$15.20M
Summit Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$0.00
N/A
Gross Margin
0.00%
N/A
Market Cap
$11.97BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$75.27M
N/A
Employees
159
N/A
Net Income
-$189.42M
-289.0%
EBITDA
-$189.38M
-289.0%
Quarterly Fundamentals
Total Cash
$454.05M
+62.2%
Total Debt
$15.20M
+204.2%
Accounts Receivable
$0.00
N/A
Inventory
$0.00
N/A
Long Term Debt
$12.79M
+467.8%
Short Term Debt
$2.41M
-12.1%
Return on Assets
-2.14%
N/A
Return on Invested Capital
-2.50%
N/A
Free Cash Flow
-$92.93M
-94.8%
Operating Cash Flow
-$92.74M
-95.7%